Nuvectis Pharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Nuvectis Pharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Nuvectis Pharma, Inc. made a loss over the last year. Nuvectis Pharma, Inc. owes $0.59 for every $1 it owns. Nuvectis Pharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNuvectis Pharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
75.09The share price is 75.09 times Nuvectis Pharma, Inc.'s book value per share, higher than almost all Healthcare companies in United States.
Market cap
$682 MThe total market value of all of Nuvectis Pharma, Inc.'s shares at today's price (share price × number of shares), larger than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$9 MWhat Nuvectis Pharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.28Net worth divided by the number of shares. The share price of $20.89 is 75.1 times this, which is the P/B above.
Return on equity (ROE)
-214.6%Nuvectis Pharma, Inc. lost 214.6% of its shareholders' money over the last year, lower than 85% of Healthcare companies in United States.
Owes vs Owns
0.59×Nuvectis Pharma, Inc. owes $0.59 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Dividend yield
NoneNuvectis Pharma, Inc. does not currently pay a dividend.
Profit growth
LossNuvectis Pharma, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Nuvectis Pharma, Inc.: $682 M ÷ $9 M (30 Jun 2026) = 75.1.
What is Nuvectis Pharma, Inc.'s return on equity?
Nuvectis Pharma, Inc. lost 214.6% of its shareholders' money over the last year, lower than 85% of Healthcare companies in United States.
How much does Nuvectis Pharma, Inc. owe compared with what it owns?
Nuvectis Pharma, Inc. owes $0.59 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Does Nuvectis Pharma, Inc. pay a dividend?
No. Nuvectis Pharma, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.